In the post-hoc analyses of the patients with HFrEF in the PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) and patients with HFpEF in the PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in Heart Failure with Preserved Ejection Fraction) trials, there was a twofold higher risk of HHF and a fourfold higher of mortality after an incident pneumonia11. The gene discussed is ACE; the disease is hydrops fetalis.